- Tackling barriers that limit access and participation for under-represented patient groups.
- Ensuring cultural relevance, language accessibility and equitable site selection.
- Embedding PROs and patient insights to shape inclusive eligibility and trial procedures.
- Measuring what matters: evaluating the impact of patient-centred designs on recruitment and retention.
- What the new national target requires from sites and sponsors
- Meeting the NIHR’s new FPI targets: 30days for Rare, 60 days for all others
- Systemic challenges slowing UK clinical trial delivery
- Enablers: streamlined processes, capacity, and perforMaria Koufali mance management
- What success looks like for 2025–2026
- The impact of the new UK clinical trial regulations coming into force in April 2026 and what they mean for sponsors, investigators, and trial delivery
- Government priorities and progress across the UK clinical research ecosystem two years on
- How artificial intelligence is transforming clinical trial design, feasibility, patient identification, and operational efficiency
- Cross-sector collaboration between regulators, industry, and the NHS to strengthen the UK’s position as a leading destination for clinical research
- Looking ahead: building a more agile, technology-enabled clinical trials environment in the UK
